➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
AstraZeneca
Moodys
McKinsey
Merck

Last Updated: June 13, 2021

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 011719


Email this page to a colleague

« Back to Dashboard

NDA 011719 describes METHOTREXATE SODIUM PRESERVATIVE FREE, which is a drug marketed by Accord Hlthcare, Hospira, Mylan Labs Ltd, Pharmachemie Bv, Sagent Pharms Inc, Sandoz Inc, and West-ward Pharms Int, and is included in thirteen NDAs. It is available from five suppliers. Additional details are available on the METHOTREXATE SODIUM PRESERVATIVE FREE profile page.

The generic ingredient in METHOTREXATE SODIUM PRESERVATIVE FREE is methotrexate sodium. There are twenty drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the methotrexate sodium profile page.
Summary for 011719
Tradename:METHOTREXATE SODIUM PRESERVATIVE FREE
Applicant:Hospira
Ingredient:methotrexate sodium
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 011719
Suppliers and Packaging for NDA: 011719
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
METHOTREXATE LPF methotrexate sodium INJECTABLE;INJECTION 011719 NDA Hospira, Inc. 61703-350 61703-350-10 5 VIAL, MULTI-DOSE in 1 CARTON (61703-350-10) > 2 mL in 1 VIAL, MULTI-DOSE (61703-350-09)
METHOTREXATE PRESERVATIVE FREE methotrexate sodium INJECTABLE;INJECTION 011719 NDA Hospira, Inc. 61703-350 61703-350-10 5 VIAL, MULTI-DOSE in 1 CARTON (61703-350-10) > 2 mL in 1 VIAL, MULTI-DOSE (61703-350-09)

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrengthEQ 20MG BASE/VIAL
Approval Date:Approved Prior to Jan 1, 1982TE:RLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrengthEQ 50MG BASE/VIAL
Approval Date:Approved Prior to Jan 1, 1982TE:RLD:No

Profile for product number 004

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrengthEQ 2.5MG BASE/ML
Approval Date:Approved Prior to Jan 1, 1982TE:RLD:No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Medtronic
Moodys
Express Scripts
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.